Literature DB >> 9059724

Cognitive function and distress after common whiplash injury.

A Smed1.   

Abstract

INTRODUCTION: In a prospective study 29 patients fulfilled the criteria of Whiplash-Associated Disorders grade III in the Quebec classification.
MATERIAL AND METHODS: One month postinjury, computerized neuropsychological tests, a clinical interview and the symptom checklist SCL-90-R were administered. Three whiplash scales were extrapolated from SCL-90-R: pain, subjective cognitive difficulties and sleep disorders. SCL-90-R was repeated 6 months later.
RESULTS: One month after the accident, 85% of the patients had resumed work. Subjective cognitive disturbances, however, were frequent but unrelated to test performances, which were within the normal range. Patients reporting stressful life events unrelated to the injury had more symptoms and elevated levels of distress on all SCL-90-R syndrome scales. At follow-up their distress was unchanged, and subjective cognitive function had deteriorated.
CONCLUSION: Stressful life events unrelated to the accident and a high level of distress 1 month postinjury may augment the risk of "late whiplash syndrome". Reassessment 3-6 weeks postinjury as recommended by the Quebec Task Force should include assessment of complicating social factors and a psychological symptom checklist.

Entities:  

Mesh:

Year:  1997        PMID: 9059724     DOI: 10.1111/j.1600-0404.1997.tb00072.x

Source DB:  PubMed          Journal:  Acta Neurol Scand        ISSN: 0001-6314            Impact factor:   3.209


  2 in total

1.  Cognitive complaints in patients after whiplash injury: the impact of malingering.

Authors:  B Schmand; J Lindeboom; S Schagen; R Heijt; T Koene; H L Hamburger
Journal:  J Neurol Neurosurg Psychiatry       Date:  1998-03       Impact factor: 10.154

2.  Temperament and character: prognostic factors in whiplash patients?

Authors:  Kurt Pettersson; Sven Brändström; Göran Toolanen; Christer Hildingsson; Per-Olof Nylander
Journal:  Eur Spine J       Date:  2004-03-27       Impact factor: 3.134

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.